20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team headed by James Hébert, Sc.D., Director of the South Carolina Statewide Cancer Prevention and Control Program and Health Sciences Distinguished Professor in the Department of Epidemiology and Biostatistics.

The technology analyzes changes in prostate-specific antigen (PSA) levels over time, thus helping to identify rapidly growing prostate tumors that pose the greatest chance of causing disability and death. This enables detection of dangerous prostate cancers even before PSA levels cross standard thresholds, typically 4.0 ng/mL according to guidelines. This permits earlier, less invasive and more effective therapeutic interventions while the tumor is still confined to the prostate organ. 20/20 BioLabs plans to incorporate the algorithm into its OneTest for Cancer platform, a blood-based multi-cancer early detection test designed to evaluate cancer risk using established protein biomarkers, clinical factors, and AI-driven analytics. The algorithm will also be made available to other clinical laboratories worldwide under software-as-a-service licenses.